Single Nucleotide Polymorphism of Interleukin-18 and Interleukin-18 Receptor and the Risk of Papillary Thyroid Cancer

Abstract

Purpose: Growing evidence suggests that interleukin-18 (IL-18) levels may affect neoplasia and that single nucleotide polymorphisms (SNPs) within IL-18 gene may influence its production. In this study, we evaluated whether IL-18 and IL-18 receptor (IL-18R) polymorphisms are associated with the development and clinicopathological features of papillary thyroid carcinoma (PTC).

Materials and Methods: Using direct sequencing, we investigated the association between functional polymorphisms of IL-18 and IL-18R genes and susceptibility to PTC in 94 PTC patients and 260 healthy controls. Genetic data were analyzed using commercially available software. Multiple logistic regression models were used to calculate odds ratios, 95% confidence intervals, and P-values for the association between the genotypes and risk of PTC. The PTC patients were further subgrouped and compared with respect to their clinicopathological characteristics.

Results: 3 SNPs of IL-18 (rs549908, rs360717, and rs187238) and one of IL-18R (rs1420106) examined in this study were significantly associated with the development of PTC. The allelic frequencies of the 3 SNPs of IL-18 also showed significant association with lymph node metastasis.

Conclusion: IL-18 and IL-18R polymorphisms may contribute to the development and lymph node metastasis of PTC.

Key words

thyroid neoplasm·interleukin-18·receptors - interleukin-18·polymorphism - single nucleotide

• References

• 1 Abubaker J, Jehan Z, Bavi P et al Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab 2008; 93: 611-618
• 2 Sinnott B, Ron E, Schneider AB. Exposing the thyroid to radiation: a review of its current extent, risks, and implications. Endocr Rev 2010; 31: 756-773
• 3 Fallah M, Pukkala E, Tryggvadottir L et al Risk of thyroid cancer in first-degree relatives of patients with non-medullary thyroid cancer by histology type and age at diagnosis: a joint study from five Nordic countries. J Med Genet 2010; 50: 373-382
• 4 Bozec A, Lassalle S, Hofman V et al The thyroid gland: a crossroad in inflammation-induced carcinoma? An ongoing debate with new therapeutic potential. Current medicinal chemistry 2010; 17: 3449-3461
• 5 Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867
• 6 Nakanishi K, Yoshimoto T, Tsutsui H et al Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001; 19: 423-474
• 7 Lee SJ, Cho YS, Cho MC et al Both E6 and E7 oncoproteins of human papilloma virus 16 inhibit IL-18-induced INF-gamma production in human peripheral blood mononuclear and NK cells. J Immunol 2001; 167: 497-504
• 8 Dinarello CA. Interleukin-18. Methods 1999; 19: 121-132
• 9 Osaki T, Peron JM, Cai Q et al INF-gamma-inducing factor/IL-18 administration mediates IFN-gamma and IL-12-independent antitumor effects. J Immunol 1998; 160: 1742-1749
• 10 Sims JE. IL-1 and IL-18 receptors, and their extended family. Curr Opin Immunol 2002; 14: 117-122
• 11 Hoshino K, Tsutsui H, Kawai T et al Cutting edge: generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J Immunol 1999; 162: 5041-5044
• 12 Cheung H, Chen NJ, Cao Z et al Accessory protein-like is essential for IL-18-mediated signaling. J Immunol 2005; 174: 5351-5357
• 13 Folwaczny M, Glas J, Török HP et al Polymorphisms of the interleukin-18 gene in periodontitis patients. J Clin Periodontol 2005; 32: 530-534
• 14 Tone M, Thompson SA, Tone Y et al Regulation of IL-18 (IFNgamma-inducing factor) gene expression. J Immunol 2005; 159: 6156-6163
• 15 Bresnihan B, Roux-Lombard P, Murphy E et al Serum interleukin 18 and interleukin 18 binding protein in rheumatoid arthritis. Ann Rheum Dis 2002; 61: 726-729
• 16 Amerio P, Frezzolini A, Abeni D et al Increased IL-18 in patients with systemic lupus erythematosus: relations with Th-1, Th-2, pro-inflammatory cytokines and disease activity. IL-18 is a marker of disease activity but does not correlate with pro-inflammatory cytokines. Clin Exp Rheumatol 2002; 20: 535-538
• 17 Pages F, Berger A, Lebel-Binay S et al Proinflammatory and antitumor properties of interleukin-18 in the gastrointestinal tract. Immunol Lett 2000; 75: 9-14
• 18 Ushio S, Namba M, Okura T. Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol 1996; 156: 4274-4279
• 19 Dinarello CA. IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999; 103: 11-24
• 20 Puren AJ, Fantuzzi G, Gu Y et al Interleukin-18 (IFN gamma-inducing factor) induces IL-8 and IL-1beta via TNF alpha production from non-CD14+ human blood mononuclear cells. Journal of Clinical Investigation 1998; 101: 711-719
• 21 Wei YS, Lan Y, Liu YG et al Interleukin-18 gene promoter polymorphisms and the risk of esophageal squamous cell carcinoma. Acta Oncol 2007; 17: 1-7
• 22 Liu Y, Lin N, Huang L et al Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA Cell Biol 2007; 26: 613-618
• 23 Nikiteas N, Yannopoulos A, Chatzitheofylaktou A et al Heterozygosity for interleukin-18 607 A/C polymorphism is associated with risk for colorectal cancer. Anticancer Res 2007; 27: 3849-3853
• 24 Farhat K, Hassen E, Bouzgarrou N et al Functional IL-18 promoter gene polymorphisms in Tunisian nasopharyngeal carcinoma patients. Cytokine 2008; 43: 132-137
• 25 Vidal-Vanaclocha F, Mendoza L, Telleria N et al Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev 2006; 25: 417-434
• 26 Takiyama Y, Miyokawa N, Tokusashi Y et al Thyroid-stimulating hormone induces interleukin-18 gene expression in FRTL-5 cells: immunohistochemical detection of interleukin-18 in autoimmune thyroid disease. Thyroid 2002; 12: 935-943
• 27 Cunha LL, Tincani AJ, Assumpção LV et al Interleukin-10 but not interleukin-18 may be associated with the immune response against well-differentiated thyroid cancer. Clinics (Sao Paulo) 2011; 66: 1203-1208
• 28 Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867
• 29 Eun YG, Shin IH, Lee YC et al Interleukin 22 polymorphisms and papillary thyroid cancer. Journal of endocrinological investigation 2013; 36: 584-587
• 30 Erdogan M, Karadeniz M, Ozbek M et al Interleukin-10 gene polymorphism in patients with papillary thyroid cancer in Turkish population. J Endocrinol Invest 2008; 31: 750-754
• 31 Eun YG, Shin IH, Kim MJ et al Associations between promoter polymorphism-106A/G of interleukin-11 receptor alpha and papillary thyroid cancer in Korean population. Surgery 2012; 151: 323-329
• 32 Lee YC, Chung JH, Kim SK et al Association between interleukin 17/interleukin 17 receptor gene polymorphisms and papillary thyroid cancer in Korean population. Cytokine 2015; 71: 283-288
• 33 Harness JK, Thompson NW, McLeod MK et al Differentiated thyroid carcinoma in children and adolescents. World J Surg 1992; 16: 547-553
• 34 McHenry CR, Rosen IB, Walfish PG. Prospective management of nodal metastases in differentiated thyroid cancer. Am J Surg 1991; 162: 353-356
• 35 Sellers M, Beenken S, Blankenship A et al Prognostic significance of cervical lymph node metastases in differentiated thyroid cancer. Am J Surg 1992; 164: 578-581
• 36 Harwood J, Clark OH, Dunphy JE. Significance of lymph node metastasis in differentiated thyroid cancer. Am J Surg 1978; 136: 107-110